Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04334174
Title Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas (BRENTICON-T)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Kansas Medical Center
Indications

adult T-cell leukemia/lymphoma

peripheral T-cell lymphoma

angioimmunoblastic T-cell lymphoma

hepatosplenic T-cell lymphoma

anaplastic large cell lymphoma

Therapies

Brentuximab vedotin

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST